Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant propranolol + SOX + toripalimab for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600131905Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol, toripalimab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathologic complete response. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
propranololtoripalimaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600131905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131905.